Studies have found that the newer Omickron subtype strain can avoid the original strain and the antibodies produced after vaccination. Even if the additive is given, it may still be infected again. ( AFP )
(Reuters, New York) A new study found that people who have been infected with the original Omickron strain may still be re-infected with other subtypes of Omickron even if they have been vaccinated with the coronavirus vaccine and additives.
Peking University Biomedical Frontier Innovation Center, Peking University School of Life Sciences and Beijing Changping Laboratory jointly conducted research, and released a report on Friday in the authoritative British scientific journal "Nature". The results show that antibodies produced by people who have been vaccinated and infected with Omickron BA.1 can neutralize Omickron BA.1 and the original strain. However, the currently spreading Omickron subtype strain has shown gene mutations and has the ability to avoid antibodies.
Researchers found through test tube experiments that newer subtype strains focus on avoiding the original strain and antibodies produced after vaccination.
study warns that vaccine additives developed based on Omickron BA.1 strain, such as those developed by Pfizer and Moderna, may not have a wide range of protective effects on other new strains of Omickron.
experiments show that the monoclonal antibody drug bebtelovimab produced by Eli Lilly and Cilgavimab contained in Evusheld produced by AstraZeneca can still effectively neutralize the strains of Omickron BA.5, BA.4 and BA.2.12.1.
Garcia Sastre, a researcher in microbial and infectious diseases at the Icahn School of Medicine in Mount Sinai, New York, suggested that to effectively defend against different variant strains, vaccines that target one or more variant strains may be developed.
However, many experts pointed out that compared with the existing coronavirus vaccine, the improved vaccine against Omickron strain is less effective. Garcia-Sastra also said that after the vaccine against a specific strain is released, a new variant of the virus may have appeared.
Modner revealed on June 8 that the new version of the vaccine produced by the company can produce a better immune response than the original version of the vaccine. (Reuters)
WHO recommends adjusting vaccine formula for Omickron variant strain
In addition, WHO Crown Vaccine Ingredients Technical Consulting Group said on Friday that vaccine formula can be adjusted for Omickron variant strain and used as an additive for the public to inoculate it to strengthen resistance. People who have received the basic vaccine series of COVID-19 may benefit.
modified vaccine must obtain emergency use approval or approved by strict national regulatory authorities before it can be used globally.
Multiple vaccine manufacturers, including Pfizer and Moderna, are developing a new generation of coronavirus vaccines that can resist both the Omickron variant strain and the original strain.
Modner revealed last week that the new version of the vaccine produced by the company can produce a better immune response than the original vaccine. European Medicines Agency has begun a rolling review of the adjusted vaccines produced by Pfizer and Moderna.
